These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 19531643

  • 1. Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms.
    Bonuccelli S, Muscelli E, Gastaldelli A, Barsotti E, Astiarraga BD, Holst JJ, Mari A, Ferrannini E.
    Am J Physiol Endocrinol Metab; 2009 Aug; 297(2):E532-7. PubMed ID: 19531643
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The Staub-Traugott effect. Evidence for multifactorial regulation of a physiological function.
    Wajngot A, Grill V, Efendić S, Cerasi E.
    Scand J Clin Lab Invest; 1982 Jun; 42(4):307-13. PubMed ID: 6753099
    [Abstract] [Full Text] [Related]

  • 4. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.
    Hare KJ, Vilsbøll T, Holst JJ, Knop FK.
    Am J Physiol Endocrinol Metab; 2010 Apr; 298(4):E832-7. PubMed ID: 20103744
    [Abstract] [Full Text] [Related]

  • 5. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
    Andersen O, Haugaard SB, Holst JJ, Deacon CF, Iversen J, Andersen UB, Nielsen JO, Madsbad S.
    HIV Med; 2005 Mar; 6(2):91-8. PubMed ID: 15807714
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.
    Lerche S, Soendergaard L, Rungby J, Moeller N, Holst JJ, Schmitz OE, Brock B.
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):500-6. PubMed ID: 19094067
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males.
    Jeibmann A, Zahedi S, Simoni M, Nieschlag E, Byrne MM.
    Eur J Clin Invest; 2005 Sep; 35(9):565-72. PubMed ID: 16128863
    [Abstract] [Full Text] [Related]

  • 10. beta-Cell function and insulin sensitivity in adolescents from an OGTT.
    Sunehag AL, Man CD, Toffolo G, Haymond MW, Bier DM, Cobelli C.
    Obesity (Silver Spring); 2009 Feb; 17(2):233-9. PubMed ID: 19057529
    [Abstract] [Full Text] [Related]

  • 11. Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet.
    Parlevliet ET, Heijboer AC, Schröder-van der Elst JP, Havekes LM, Romijn JA, Pijl H, Corssmit EP.
    Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E142-7. PubMed ID: 17971509
    [Abstract] [Full Text] [Related]

  • 12. [Insulin release and daily glucose change in polycystic ovary syndrome women with normal glucose tolerance].
    Tao MF, Zhu JP, Zhou J, Lu W, Qin W, Teng YC, Jia WP.
    Zhonghua Yi Xue Za Zhi; 2009 Mar 17; 89(10):659-63. PubMed ID: 19595057
    [Abstract] [Full Text] [Related]

  • 13. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF, Nilas L, Madsbad S, Holst JJ.
    Metabolism; 2009 May 17; 58(5):586-93. PubMed ID: 19375579
    [Abstract] [Full Text] [Related]

  • 14. Enteral infusion of glucose at rates approximating EGP enhances glucose disposal but does not cause hypoglycemia.
    Zangeneh F, Basu R, Shah P, Arora P, Camilleri M, Rizza RA.
    Am J Physiol Endocrinol Metab; 2003 Aug 17; 285(2):E280-6. PubMed ID: 12857674
    [Abstract] [Full Text] [Related]

  • 15. A mathematical model of the oral glucose tolerance test illustrating the effects of the incretins.
    Brubaker PL, Ohayon EL, D'Alessandro LM, Norwich KH.
    Ann Biomed Eng; 2007 Jul 17; 35(7):1286-300. PubMed ID: 17393338
    [Abstract] [Full Text] [Related]

  • 16. [Characteristics of glycemic excursion in different subtypes of impaired glucose intolerance].
    Kang Y, Lu JM, Sun JF, Li CL, Wang XL, Zhang XQ, Lü ZH, Dou JT, Mu YM.
    Zhonghua Yi Xue Za Zhi; 2009 Mar 17; 89(10):669-72. PubMed ID: 19595059
    [Abstract] [Full Text] [Related]

  • 17. Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test.
    Thomaseth K, Pavan A, Berria R, Glass L, DeFronzo R, Gastaldelli A.
    Comput Methods Programs Biomed; 2008 Feb 17; 89(2):132-40. PubMed ID: 17706318
    [Abstract] [Full Text] [Related]

  • 18. Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT.
    Hovorka R, Shojaee-Moradie F, Carroll PV, Chassin LJ, Gowrie IJ, Jackson NC, Tudor RS, Umpleby AM, Jones RH.
    Am J Physiol Endocrinol Metab; 2002 May 17; 282(5):E992-1007. PubMed ID: 11934663
    [Abstract] [Full Text] [Related]

  • 19. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects.
    Steinert RE, Poller B, Castelli MC, Friedman K, Huber AR, Drewe J, Beglinger C.
    Clin Pharmacol Ther; 2009 Dec 17; 86(6):644-50. PubMed ID: 19727071
    [Abstract] [Full Text] [Related]

  • 20. Evaluating the glucose tolerance test in mice.
    Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J.
    Am J Physiol Endocrinol Metab; 2008 Dec 17; 295(6):E1323-32. PubMed ID: 18812462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.